title: Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
abstract: OBJECTIVE
  To describe the intraocular pressure (IOP)-lowering effects in eyes with open-angle glaucoma (OAG) after treatment with an anterior juxtascleral depot of anecortave acetate.
  
  
  METHODS
  Prospective, interventional case series.
  
  
  METHODS
  Seven eyes of six subjects with OAG, with uncontrolled IOP while being administered one or more topical medications, received 24 mg anecortave acetate delivered by anterior juxtascleral depot. IOP was assessed at baseline and regularly after treatment for up to 24 months.
  
  
  RESULTS
  Mean IOP before anecortave acetate treatment was 31.3 +/- 11.3 mm Hg and dropped by 9.5 +/- 4.5 mm Hg (32.7% +/- 16.8%) within one week after treatment. This IOP reduction was sustained through six months (8.4 +/- 5.4 mm Hg [29.6% +/- 12.4%]) and 12 months (9.5 +/- 5.7 mm Hg [34.0% +/- 15.9%]) after a single anecortave acetate treatment. The injection process was well tolerated, and no eyes experienced any injection-related or drug-related serious adverse events.
  
  
  CONCLUSIONS
  Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.
authors.affiliation: Wilmer Institute and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. arobin@glaucomaexpert.com
authors.forename: Alan L
authors.initials: AL
authors.lastname: Robin
authors.forename: Abbot F
authors.initials: AF
authors.lastname: Clark
authors.forename: David W
authors.initials: DW
authors.lastname: Covert
authors.forename: Scott
authors.initials: S
authors.lastname: Krueger
authors.forename: Michael V W
authors.initials: MV
authors.lastname: Bergamini
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Landry
authors.forename: Jaime E
authors.initials: JE
authors.lastname: Dickerson
authors.forename: Sally A
authors.initials: SA
authors.lastname: Scheib
authors.forename: Tony
authors.initials: T
authors.lastname: Realini
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Defaller
authors.forename: Gerald D
authors.initials: GD
authors.lastname: Cagle
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000869:Anterior Eye Segment; D016503:Drug Delivery Systems; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011244:Pregnadienediols / Q000008:administration & dosage*; D011446:Prospective Studies; D012590:Sclera; D014065:Tonometry, Ocular
chemical_list: D020533:Angiogenesis Inhibitors; D011244:Pregnadienediols; C418047:anecortave acetate